Association of Physician Associates in Obstetrics and Gynecology

Home | Member Login | Join/Renew | Jobs | Contact

Home
About
Career Center
Education
Events
- 2024 Annual Conference
- 2023 Annual Conference
  - 2023 Schedule
  - Meet the Speakers
Membership
Resources

Avoiding Dolutegravir in Young Women With HIV: Time for a Rethink?

April 02, 2019 3:34 PM | Deleted user

April 2, 2019, MedPage Today

Total deaths for women with HIV and their children are projected to be lower with dolutegravir-based (Tivicay) antiretroviral therapy (ART) versus efavirenz-based (Sustiva) ART, a model-based analysis found.

Read more.

563 Carter Court, Suite B, Kimberly, WI 54136
920-560-5620 / 800-545-0636
920-882-3655 (fax)
Email: APAOG@badgerbay.co

Quick Links

About APAOG
Contact Us
Join as a Member

Avoiding Dolutegravir in Young Women With HIV: Time for a Rethink?

April 02, 2019 3:34 PM | Deleted user

Association of Physician Associates in Obstetrics and Gynecology

Follow Us